Xencor Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
60,259.00
16,422.00
17,592.00
23,625.00
48,925.00
70,409
Depreciation, Depletion & Amortization
711.00
882.00
1,113.00
1,466.00
2,030.00
3,251
Other Funds
8,020.00
8.00
-
-
-
20,569
Funds from Operations
9,394.00
13,172.00
10,232.00
35,392.00
29,920.00
46,589
Changes in Working Capital
3,941.00
8,179.00
36,898.00
59,225.00
3,763.00
33,167
Net Operating Cash Flow
5,453.00
21,351.00
26,666.00
94,617.00
33,683.00
79,756
Capital Expenditures
1,294.00
2,285.00
3,675.00
3,009.00
7,278.00
Sale of Fixed Assets & Businesses
16.00
2.00
9.00
-
-
Purchase/Sale of Investments
-
-
181,440.00
210,644.00
39,228.00
Net Investing Cash Flow
1,278.00
2,283.00
185,106.00
213,653.00
31,950.00
Net Financing Cash Flow
82,394.00
308.00
116,381.00
120,974.00
3,733.00
Net Change in Cash
75,663.00
23,326.00
42,059.00
1,938.00
2,000.00
Free Cash Flow
5,589.00
22,131.00
24,736.00
93,110.00
38,994.00
Deferred Taxes & Investment Tax Credit
-
-
-
65.00
-
-
Change in Capital Stock
90,414.00
316.00
116,381.00
120,974.00
3,733.00

About Xencor

View Profile
Address
111 West Lemon Avenue
Monrovia California 91016
United States
Employees -
Website http://www.xencor.com
Updated 07/08/2019
Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I.